We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Drug Targets – Products

New chief science officer, Dr. Lisa Jones
Product News

GenNext Technologies Appoints Dr. Lisa Jones of UCSD to the Role of Chief Science Officer

GenNext Technologies, Inc. has selected Dr. Lisa Jones as the company’s new chief science officer.
A closeup of many different medications
Product News

Pheno Therapeutics Announces Worldwide License From UCB to a Novel Program for Neurodegenerative Disease

Pheno Therapeutics Limited has announced that it has entered into an exclusive worldwide license agreement with UCB.
Consistency is Key to Further Drug Discovery Research content piece image
App Note / Case Study

Consistency is Key to Further Drug Discovery Research

Energy metabolism plays a central role in a wide variety of cellular and physiological processes. Therefore, a deep understanding of how disruption to energy metabolism impacts cells can help in therapeutic drug discovery and development.
The logos of Alnylam Pharmaceuticals and Paradigm4.
Product News

Foundational Partnership With Paradigm4 Enables Alnylam Pharmaceuticals To Accelerate RNAi-Based Drug Target Discovery

Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.
Ubiquigent logo
Product News

Ubiquigent Appoints Dr. Sheelagh Frame, CSO, to its Board of Directors

Ubiquigent Limited today announced the appointment of Dr. Sheelagh Frame, Chief Scientific Officer, to the Company’s Board of Directors.
MACSima™ Imaging Platform – The Next Level of Context in Spatial Biology content piece image
Product
Advertisement

MACSima™ Imaging Platform – The Next Level of Context in Spatial Biology

The MACSima™ Imaging Platform opens the next level of context in spatial biology, allowing fully automated imaging of 100s of protein markers on a single tissue sample. It includes a broad portfolio of pre-validated antibodies and an easy-to-use software generating ready-to-publish images and charts.
bit.bio Adds Two New Human Cell Products To Accelerate Research and Drug Discovery for Neurodegenerative Disease content piece image
Product News

bit.bio Adds Two New Human Cell Products To Accelerate Research and Drug Discovery for Neurodegenerative Disease

Cell coding company bit.bio has announced an expansion to its product portfolio to enable scientists to study neurodegenerative diseases in a human context.
Molecular Devices and HeartBeat.bio Announce Collaboration To Automate and Scale Cardiac Organoids content piece image
Product News

Molecular Devices and HeartBeat.bio Announce Collaboration To Automate and Scale Cardiac Organoids

Molecular Devices, LLC. and HeartBeat.bio AG, a biotech company developing cardiac organoids for drug discovery, have entered into a co-development agreement.
PhoreMost Enters Multi-Project Drug Target Discovery Collaboration With Roche content piece image
Product News

PhoreMost Enters Multi-Project Drug Target Discovery Collaboration With Roche

PhoreMost Ltd. today announced it has entered into a multi-project target discovery collaboration with Roche.
Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Bioanalysis and Drug Monitoring content piece image
Product News

Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Bioanalysis and Drug Monitoring

Bio-Rad Laboratories, Inc. today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies specific to brentuximab vedotin, secukinumab and the secukinumab–interleukin 17A drug-target complex.
Advertisement